Catalyst Clinical Research announced that Nik Morton, the company's president and COO, assumed its CEO role on 12 February 2024. Mr. Morton joined Catalyst as its COO in 2022. Mr. Morton moved into his new position while Nick Dyer, Catalyst's former CEO, has shifted his focus to overseeing the strategic growth of the companies within Project Constellation Holdings, the parent company of Catalyst Clinical Research and Genpro Research.
Prior to Mr. Morton joining Catalyst, he held strategic roles at PPD, including global leaderships roles for biostatistics, programming, medical writing, including functional services delivery; hematology and oncology project management overseeing full-service delivery; site and patient access—accountable for selecting the best sites for enrolling and for activating in the shortest cycle times; and the design and implementation of digitally enabled and decentralized clinical trials.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!